- Home
- VRSN vs RPRX Comparison
VRSN vs RPRX Comparison
Compare VRSN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRSN | RPRX |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 19.5B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRSN | RPRX |
|---|---|---|
| Price | $270.56 | $49.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $317.67 | $51.40 |
| AVG Volume (30 Days) | 833.1K | ★ 2.5M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | 1.19% | ★ 1.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.24 | 1.78 |
| Revenue | $1,656,600,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $6.78 | $38.63 |
| Revenue Next Year | $5.37 | $4.73 |
| P/E Ratio | $42.95 | ★ $28.12 |
| Revenue Growth | ★ 6.37 | 5.06 |
| 52 Week Low | $209.34 | $31.97 |
| 52 Week High | $310.60 | $50.47 |
Technical Indicators
Market Signals| Indicator | VRSN | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.49 | 58.41 |
| Support Level | $260.30 | $35.34 |
| Resistance Level | $274.69 | $50.08 |
| Average True Range (ATR) | 7.56 | 0.85 |
| MACD | -1.25 | -0.06 |
| Stochastic Oscillator | 75.18 | 58.46 |
Price Performance
Historical ComparisonAbout VRSN VeriSign Inc.
Verisign is an operator of critical infrastructure within the domain name system, or DNS. As the registry for some of the world's most popular TLDs, .com and .net, Verisign directs DNS resolvers to the appropriate registry where IP addresses are stored. Verisign's control over its TLDs is regulated by ICANN and the NTIA and are subject to contract renewal every six years. The company generates revenue through annual subscriptions allowing customers to use .com and .net as their TLD of choice for their respective websites.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.